SE0302488D0 - New combination - Google Patents

New combination

Info

Publication number
SE0302488D0
SE0302488D0 SE0302488A SE0302488A SE0302488D0 SE 0302488 D0 SE0302488 D0 SE 0302488D0 SE 0302488 A SE0302488 A SE 0302488A SE 0302488 A SE0302488 A SE 0302488A SE 0302488 D0 SE0302488 D0 SE 0302488D0
Authority
SE
Sweden
Prior art keywords
new combination
active ingredient
kit
treatment
receptor antagonist
Prior art date
Application number
SE0302488A
Other languages
English (en)
Inventor
Nigel Boughton-Smith
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0302488A priority Critical patent/SE0302488D0/sv
Publication of SE0302488D0 publication Critical patent/SE0302488D0/sv
Priority to KR1020067005446A priority patent/KR20060086942A/ko
Priority to NZ545964A priority patent/NZ545964A/en
Priority to AU2004271886A priority patent/AU2004271886B2/en
Priority to JP2006526854A priority patent/JP2007505900A/ja
Priority to CA002538416A priority patent/CA2538416A1/en
Priority to RU2006112423/15A priority patent/RU2338556C2/ru
Priority to EP04775437A priority patent/EP1663224A1/en
Priority to TW093127889A priority patent/TW200526199A/zh
Priority to MXPA06002722A priority patent/MXPA06002722A/es
Priority to BRPI0414558-5A priority patent/BRPI0414558A/pt
Priority to US10/572,276 priority patent/US20070082930A1/en
Priority to PCT/SE2004/001334 priority patent/WO2005025571A1/en
Priority to CNA2004800284582A priority patent/CN1859911A/zh
Priority to UY28517A priority patent/UY28517A1/es
Priority to ARP040103356A priority patent/AR045783A1/es
Priority to IL173913A priority patent/IL173913A0/en
Priority to ZA200602260A priority patent/ZA200602260B/xx
Priority to IS8396A priority patent/IS8396A/is
Priority to NO20061662A priority patent/NO20061662L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
SE0302488A 2003-09-18 2003-09-18 New combination SE0302488D0 (sv)

Priority Applications (20)

Application Number Priority Date Filing Date Title
SE0302488A SE0302488D0 (sv) 2003-09-18 2003-09-18 New combination
CNA2004800284582A CN1859911A (zh) 2003-09-18 2004-09-15 包括p2x7受体拮抗剂和非甾体抗炎药的药物组合物
TW093127889A TW200526199A (en) 2003-09-18 2004-09-15 New combination
BRPI0414558-5A BRPI0414558A (pt) 2003-09-18 2004-09-15 composição farmacêutica compreendendo um antagonista do receptor p2x7 e uma droga antiinflamatória não esteróide
AU2004271886A AU2004271886B2 (en) 2003-09-18 2004-09-15 A pharmaceutical composition comprising a P2X7 receptor antagonist and a nonsteroidal anti inflammatory drug.
JP2006526854A JP2007505900A (ja) 2003-09-18 2004-09-15 Ｐ２ｘ７受容体アンタゴニストおよび非ステロイド性抗炎症薬を含有してなる医薬組成物
CA002538416A CA2538416A1 (en) 2003-09-18 2004-09-15 A pharmaceutical composition comprising a p2x7 receptor antagonist and a nonsteroidal anti inflammatory drug.
RU2006112423/15A RU2338556C2 (ru) 2003-09-18 2004-09-15 Фармацевтическая композиция, содержащая антагонист p2x7-рецептора и нестероидное противовоспалительное лекарственное средство
EP04775437A EP1663224A1 (en) 2003-09-18 2004-09-15 A pharmaceutical composition comprising a p2x7 receptor antagonist and a nonsteroidal anti inflammatory drug
KR1020067005446A KR20060086942A (ko) 2003-09-18 2004-09-15 Ｐ2ｘ7 수용체 길항제 및 비스테로이드성 소염 약물을포함하는 제약 조성물
MXPA06002722A MXPA06002722A (es) 2003-09-18 2004-09-15 Composicion farmaceutica que comprende un antagonista del receptor p2x7 y un farmaco anti-inflamatorio no esteroidal.
NZ545964A NZ545964A (en) 2003-09-18 2004-09-15 A pharmaceutical composition comprising a P2X7 receptor antagonist and a nonsteroidal anti-inflammatory drug
US10/572,276 US20070082930A1 (en) 2003-09-18 2004-09-15 Pharmaceutical composition comprising a p2x7 receptor antagonist and a nonsteroidal anti-inflammatory drug
PCT/SE2004/001334 WO2005025571A1 (en) 2003-09-18 2004-09-15 A pharmaceutical composition comprising a p2x7 receptor antagonist and a nonsteroidal anti inflammatory drug.
UY28517A UY28517A1 (es) 2003-09-18 2004-09-16 Nueva combinación
ARP040103356A AR045783A1 (es) 2003-09-18 2004-09-17 Composición farmacéutica que comprende un antagonista del receptor p2x7 y una droga anti-inflamatoria no esteroide
IL173913A IL173913A0 (en) 2003-09-18 2006-02-23 A pharmaceutical composition comprising a p2x7 receptor antagonist and a nonsteroidal anti inflammatory drug
ZA200602260A ZA200602260B (en) 2003-09-18 2006-03-17 A pharmaceutical composition comprising a P2X7 receptor antagonist and a nonsteroidal anti-inflammatory drug
IS8396A IS8396A (is) 2003-09-18 2006-04-03 Lyfjablanda sem felur í sér P2X7 viðtakamótlyf ogbólgueyðandi lyf án stera
NO20061662A NO20061662L (no) 2003-09-18 2006-04-11 Farmasoytisk preparat omfattende en P2X7 reseptorantagonisk og ikke-steroid intiinfammatorisk medikament

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0302488A SE0302488D0 (sv) 2003-09-18 2003-09-18 New combination

Publications (1)

Publication Number Publication Date
SE0302488D0 true SE0302488D0 (sv) 2003-09-18

Family

ID=29212490

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0302488A SE0302488D0 (sv) 2003-09-18 2003-09-18 New combination

Country Status (20)

Country Link
US (1) US20070082930A1 (sv)
EP (1) EP1663224A1 (sv)
JP (1) JP2007505900A (sv)
KR (1) KR20060086942A (sv)
CN (1) CN1859911A (sv)
AR (1) AR045783A1 (sv)
AU (1) AU2004271886B2 (sv)
BR (1) BRPI0414558A (sv)
CA (1) CA2538416A1 (sv)
IL (1) IL173913A0 (sv)
IS (1) IS8396A (sv)
MX (1) MXPA06002722A (sv)
NO (1) NO20061662L (sv)
NZ (1) NZ545964A (sv)
RU (1) RU2338556C2 (sv)
SE (1) SE0302488D0 (sv)
TW (1) TW200526199A (sv)
UY (1) UY28517A1 (sv)
WO (1) WO2005025571A1 (sv)
ZA (1) ZA200602260B (sv)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
SE0300480D0 (sv) 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
JP2007501270A (ja) * 2003-05-29 2007-01-25 アストラゼネカ・アクチエボラーグ Ｐ２Ｘ７受容体アンタゴニストおよび腫瘍壊死因子αを含む医薬組成物
EP1644041A1 (en) * 2003-05-29 2006-04-12 AstraZeneca AB A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
US20070281931A1 (en) * 2003-05-29 2007-12-06 Nigel Boughton-Smith Pharmaceutical Composition Containing a P2x7 Receptor Antagonist and Methotrexate
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
SA05260265A (ar) * 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
SE0402925D0 (sv) * 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds
US20080207577A1 (en) * 2005-07-11 2008-08-28 Astrazeneca Ab Combination I
WO2007008157A1 (en) * 2005-07-11 2007-01-18 Astrazeneca Ab New combination 2
EP1991233A4 (en) * 2006-02-17 2009-07-01 Avalon Pharmaceuticals Hydroxypiperidine derivatives and their use
WO2009074518A1 (en) * 2007-12-12 2009-06-18 Glaxo Group Limited Combinations of prolinamide p2x7 modulators with further therapeutic agents
GB0724258D0 (en) * 2007-12-12 2008-01-30 Glaxo Group Ltd Novel combinations
GB0919594D0 (en) 2009-11-09 2009-12-23 Glaxo Group Ltd Compounds
US8691556B2 (en) 2009-12-08 2014-04-08 Vanderbilt University Methods and compositions for vein harvest and autografting
EP2542670A2 (en) 2010-03-05 2013-01-09 President and Fellows of Harvard College Induced dendritic cell compositions and uses thereof
WO2013082565A1 (en) * 2011-12-02 2013-06-06 Michael Kaleko Therapies for disorders of the cornea and conjunctiva
CN111904926B (zh) * 2014-09-10 2023-10-10 Gsk消费者健康有限责任公司 局部用双氯芬酸钠组合物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471491A (en) * 1967-08-28 1969-10-07 Squibb & Sons Inc Adamantyl-s-triazines
US3464998A (en) * 1968-03-04 1969-09-02 Searle & Co Adamantyl esters and amides of pyridinecarboxylic acids
US4349552A (en) * 1978-10-30 1982-09-14 Fujisawa Pharmaceutical Company, Ltd. 5-Fluorouracil derivatives, and their pharmaceutical compositions
US4751292A (en) * 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
US5399564A (en) * 1991-09-03 1995-03-21 Dowelanco N-(4-pyridyl or 4-quinolinyl) arylacetamide and 4-(aralkoxy or aralkylamino) pyridine pesticides
DE69738949D1 (de) * 1996-05-20 2008-10-09 Darwin Discovery Ltd Chinolincarboxamide als tnf-inhibitoren und als pde-iv inhibitoren
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704544D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
RU2254333C2 (ru) * 1999-04-09 2005-06-20 Астразенека Аб Производные адамантана, способ их получения, фармацевтическая композиция на их основе и способы лечения
SE9904505D0 (sv) * 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
TWI258462B (en) * 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
SK9022002A3 (en) * 1999-12-22 2003-03-04 Pharmacia Corp Sustained-release formulation of a cyclooxygenase-2 inhibitor
GB0013737D0 (en) * 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
MXPA03011908A (es) * 2001-07-02 2004-06-03 Akzo Nobel Nv Derivados de tetrahidroquinolina.
PA8557501A1 (es) * 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
WO2003042190A1 (en) * 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
SE0103836D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Novel compounds
US6908939B2 (en) * 2001-12-21 2005-06-21 Galderma Research & Development S.N.C. Biaromatic ligand activators of PPARγ receptors
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
SE0300445D0 (sv) * 2003-02-18 2003-02-18 Astrazeneca Ab New combination
SE0300480D0 (sv) * 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
US20070281931A1 (en) * 2003-05-29 2007-12-06 Nigel Boughton-Smith Pharmaceutical Composition Containing a P2x7 Receptor Antagonist and Methotrexate
JP2007501270A (ja) * 2003-05-29 2007-01-25 アストラゼネカ・アクチエボラーグ Ｐ２Ｘ７受容体アンタゴニストおよび腫瘍壊死因子αを含む医薬組成物
EP1644041A1 (en) * 2003-05-29 2006-04-12 AstraZeneca AB A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
WO2005025571A1 (en) 2005-03-24
NO20061662L (no) 2006-04-11
NZ545964A (en) 2009-09-25
US20070082930A1 (en) 2007-04-12
BRPI0414558A (pt) 2006-11-07
IS8396A (is) 2006-04-03
AU2004271886B2 (en) 2008-03-20
MXPA06002722A (es) 2006-06-06
IL173913A0 (en) 2006-07-05
JP2007505900A (ja) 2007-03-15
CN1859911A (zh) 2006-11-08
AR045783A1 (es) 2005-11-16
KR20060086942A (ko) 2006-08-01
CA2538416A1 (en) 2005-03-24
EP1663224A1 (en) 2006-06-07
TW200526199A (en) 2005-08-16
AU2004271886A1 (en) 2005-03-24
RU2338556C2 (ru) 2008-11-20
UY28517A1 (es) 2005-04-29
RU2006112423A (ru) 2007-11-10
ZA200602260B (en) 2007-07-25

Similar Documents

Publication Publication Date Title
SE0302488D0 (sv) New combination
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
CY1118179T1 (el) Φαρμακευτικη συνθεση
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
CY1114420T1 (el) Φαρμακευτικη συνθεση για δερματικη χρηση που περιλαμβανει καλσιποτριολη και βηταμεθαζονη για την αγωγη της ψωριασης
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
ATE354362T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
CY1106927T1 (el) Φαρμακευτικη συνθεση ενος pde4 ή pde3/4 αναστολεα και ανταγωνιστη υποδοχεα ισταμινης
ECSP045171A (es) Régimen de dosificación y composición farmacéutica para anticoncepción de emergencia
MXPA05012705A (es) Una composicion farmaceutica que comprende un antagonista del receptor p2x7 y un factor alfa de necrosis tumoral.
BRPI0516749B8 (pt) composições compreendendo antagonistas dos receptores 5-ht2a e 5-ht6 e uso destes para o tratamento de distúrbios cognitivos
ATE454385T1 (de) Hiv-integrase-hemmers, pharmazeutischen zusammensetzung und ihre anwendung
MXPA05012358A (es) Combinacion farmaceutica que comprende modafinilo y otra droga.
ATE432068T1 (de) Cetirizin und pseudoephedrin enthaltende tablette
CL2009000980A1 (es) Uso de (s)-n-(2-(1,6,8-tetrahidro-2h-inden[5,4-b]furan-8-il)etil]propionamida en combinacion con una o más drogas seleccionadas de un grupo definido para preparar un medicamento útil para la prevencion o tratamiento de la depresión o desórdenes de ansiedad (divisional de la solicitud 749-2006).
SE0300445D0 (sv) New combination
SE9903995D0 (sv) New combination
ITRM20030363A0 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico diesse.
BG108452A (en) Tablet comprising cetirizine and pseudoephedrine
AR032422A1 (es) Uso de inhibidores de il-18 para el tratamiento y/o prevencion de la enfermedad cardiaca
ATE460934T1 (de) Pharmazeutische zubereitungen von ciprofloxacin
DE60305053D1 (de) Pyrimidinderivate als selektive cox-2-inhibitoren
DK1420789T3 (da) Anvendelse af aktivstoffer med my-opioid-receptoragonistisk virkning og opioid-receptorantagonistisk virkning som kombinationslægemidler til cancerbehandling
ITRM20030394A0 (it) Uso dell'indometacina e derivati come farmaci antivirali e relative composizioni farmaceutiche.
HRP20050497B1 (en) Use of levocetirizine for the persistent allergic rhinitis